Celgene (CELG) delivered a strong first-quarter earnings report Friday and a regulatory update on its delayed multiple sclerosis drug that took the worst-case scenario off the table.

The beleaguered biotech hasn’t fixed all its problems quite yet, but Friday’s business update didn’t give investors another reason to hate them, so it feels like a win. Shares of Celgene were up 3 percent to $87.70 in morning trading.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • we need a hit and perhaps some executive salary reductions due to very poor business decisions,i.e. the buying of companies with better promises and poor results.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy